SUNPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.9
| Stock Code | SUNPHARMA | Market Cap | 4,26,796 Cr. | Current Price | 1,780 ₹ | High / Low | 1,851 ₹ |
| Stock P/E | 97.8 | Book Value | 99.2 ₹ | Dividend Yield | 0.90 % | ROCE | 16.8 % |
| ROE | 17.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,743 ₹ | DMA 200 | 1,712 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.60 % | PAT Qtr | 872 Cr. | PAT Prev Qtr | 564 Cr. |
| RSI | 54.4 | MACD | 23.9 | Volume | 25,18,812 | Avg Vol 1Wk | 24,88,787 |
| Low price | 1,547 ₹ | High price | 1,851 ₹ | PEG Ratio | 1.34 | Debt to equity | 0.56 |
| 52w Index | 76.6 % | Qtr Profit Var | -24.6 % | EPS | 16.7 ₹ | Industry PE | 27.6 |
🔎 Analysis: SUNPHARMA is trading at ₹1,780, above its 50 DMA (₹1,743) and 200 DMA (₹1,712), showing medium-term strength. RSI at 54.4 is neutral, while MACD at 23.9 indicates positive momentum. Volume is slightly above the 1-week average, suggesting steady participation. Intraday trade is favorable with cautious entry and disciplined exits.
💰 Optimal Buy Price: ₹1,770–₹1,785 if price sustains above 50 DMA support.
📈 Profit Exit Levels: ₹1,810 (first target), ₹1,835 (second target near recent high).
📉 Stop-Loss: ₹1,760 to protect against downside risk.
⏱️ If Already Holding: Exit near ₹1,810 if momentum slows. Trail stop-loss below ₹1,770. Exit immediately if price breaks ₹1,760 with strong volume.
✅ Positive
- Strong ROE (17.8%) and ROCE (16.8%) indicate efficient capital usage.
- Quarterly PAT improved sequentially (₹872 Cr vs ₹564 Cr).
- DII holdings increased (+0.60%), showing domestic investor confidence.
- PEG ratio of 1.34 suggests reasonable valuation relative to growth.
⚠️ Limitation
- Stock P/E (97.8) is far above industry average (27.6), making it expensive.
- Book value is low (₹99.2) compared to current price, indicating stretched valuation.
- Quarterly profit variation (-24.6%) shows volatility in earnings.
- FII holdings decreased (-0.43%), reflecting reduced foreign confidence.
📉 Company Negative News
- High valuation multiples raise concerns about sustainability.
- Profit variation (-24.6%) highlights earnings inconsistency.
📊 Company Positive News
- Sequential PAT growth shows operational improvement.
- DII inflows support domestic sentiment.
- Dividend yield of 0.90% adds stability for investors.
💊 Industry
- Pharma sector average P/E is 27.6, much lower than SUNPHARMA’s 97.8.
- Sector momentum remains strong due to healthcare demand and global exports.
📝 Conclusion
SUNPHARMA shows medium-term strength with positive momentum indicators and strong ROE/ROCE. However, high valuations and earnings volatility limit upside. Intraday traders can consider entry near ₹1,770–₹1,785 with strict stop-loss at ₹1,760. Profit-taking should be quick at ₹1,810–₹1,835. Momentum is favorable, but valuation risks require caution.
Would you like me to extend this into a basket overlay with peers like Dr. Reddy’s, Cipla, and Lupin? That way, you can benchmark SUNPHARMA’s intraday setup against the broader pharma sector momentum for stronger confirmation signals.